Grace A. Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Grace A. Lin has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Kathryn A. Phillips
Kathryn A. Phillips, University of California San Francisco
6 shared publications- Chien-Wen Tseng
Department of Family Medicine and Community Health, University of Hawaii John A. Burns School of Medicine, Honolulu
3 shared publications Janet M. Coffman
Janet M. Coffman, University of California San Francisco
3 shared publications- R. Adams Dudley
Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Minnesota, Minneapolis, MN, United States
3 shared publications A. Mark Fendrick
Center for Value-Based Insurance Design, University of Michigan, USA
2 shared publications- Colette DeJong
VA Palo Alto Health Care System, Palo Alto, California, USA; Division of Cardiology, Stanford University School of Medicine, Palo Alto, California, USA
2 shared publications
Latest Publications
- 1 January 2026
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 45 (1) , 63-67
Use Of Independent Medical Review: Almost One-Half Of Coverage Denials Overturned
Independent medical review is an important, underused source of data to illuminate the insurance coverage landscape. During the period 2019-23, almost one-half of health plan coverage denials that were appealed to independent medical review in four states were overturned. One-third of cancer genetic testing denials were overturned, with variation by state, cancer, and test.
- 1 January 2026
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 45 (1) , 63-67
Use Of Independent Medical Review: Almost One-Half Of Coverage Denials Overturned
Independent medical review is an important, underused source of data to illuminate the insurance coverage landscape. During the period 2019-23, almost one-half of health plan coverage denials that were appealed to independent medical review in four states were overturned. One-third of cancer genetic testing denials were overturned, with variation by state, cancer, and test.
- Open Access
- 1 April 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 105 (2) , 433-442
Alzheimer's disease blood-based biomarker testing: A stakeholder-informed assessment of coverage considerations
Background: Recently published clinical studies suggest that blood-based biomarker tests (BBMTs) for Alzheimer's disease (AD) provide value, but in the U.S., neither public nor private payers currently cover these tests. Objective: To describe considerations for payer coverage of AD BBMTs that would need to be addressed to facilitate timely diagnosis and equitable patient access if clinical utility is demonstrated. Methods: We performed a targeted literature review to characterize predictable coverage barriers for BBMTs and inform the development of an interview guide. We conducted semi-structured interviews with clinicians, researchers, test developers, and a patient advocate and former payer (N = 12) to assess the barriers and refine the proposed key considerations for obtaining payer coverage. Results: Stakeholders noted that payers will require evidence of clinical validity and utility of BBMTs as part of their coverage determinations contingent on the specific indication for testing, with insufficient evidence for screening applications currently. Stakeholders also agreed that there are evidence gaps for use of BBMTs in patients from ethnic and racial minority communities that must be addressed. Given the shortage of memory specialists, stakeholders noted that limiting testing coverage authorization to specialists could be harmful to patients, particularly the underserved. Interviewees also agreed that patients with mild cognitive impairment or early-stage AD could benefit from earlier diagnosis to avoid progressing to moderate disease and limiting eligibility for new disease-modifying therapies. Conclusions: If BBMTs meet criteria for clinical utility, anticipating and planning for coverage and reimbursement before widespread implementation will be critical to ensuring broad, equitable access to BBMTs.
- 1 April 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 105 (2) , 433-442
Open AccessAlzheimer's disease blood-based biomarker testing: A stakeholder-informed assessment of coverage considerations
Background: Recently published clinical studies suggest that blood-based biomarker tests (BBMTs) for Alzheimer's disease (AD) provide value, but in the U.S., neither public nor private payers currently cover these tests. Objective: To describe considerations for payer coverage of AD BBMTs that would need to be addressed to facilitate timely diagnosis and equitable patient access if clinical utility is demonstrated. Methods: We performed a targeted literature review to characterize predictable coverage barriers for BBMTs and inform the development of an interview guide. We conducted semi-structured interviews with clinicians, researchers, test developers, and a patient advocate and former payer (N = 12) to assess the barriers and refine the proposed key considerations for obtaining payer coverage. Results: Stakeholders noted that payers will require evidence of clinical validity and utility of BBMTs as part of their coverage determinations contingent on the specific indication for testing, with insufficient evidence for screening applications currently. Stakeholders also agreed that there are evidence gaps for use of BBMTs in patients from ethnic and racial minority communities that must be addressed. Given the shortage of memory specialists, stakeholders noted that limiting testing coverage authorization to specialists could be harmful to patients, particularly the underserved. Interviewees also agreed that patients with mild cognitive impairment or early-stage AD could benefit from earlier diagnosis to avoid progressing to moderate disease and limiting eligibility for new disease-modifying therapies. Conclusions: If BBMTs meet criteria for clinical utility, anticipating and planning for coverage and reimbursement before widespread implementation will be critical to ensuring broad, equitable access to BBMTs.
- 12 December 2024
- Published by Elsevier in Healthcare
- Vol. 14 (1) , 100755
Corrigendum to “Reading the crystal ball: Primary care implications while awaiting outcomes for multi-cancer early detection tests” [Healthcare 11 (2023) 100705]
- 12 December 2024
- Published by Elsevier in Healthcare
- Vol. 14 (1) , 100755
Corrigendum to “Reading the crystal ball: Primary care implications while awaiting outcomes for multi-cancer early detection tests” [Healthcare 11 (2023) 100705]
- 8 October 2024
- Published by American Medical Association (AMA) in JAMA
- Vol. 332 (14) , 1208
State Biomarker Testing Insurance Coverage Laws—Reply
In Reply We appreciate the comments from Ms Lacasse and colleagues regarding our recently published Viewpoint examining the current landscape of state
- 8 October 2024
- Published by American Medical Association (AMA) in JAMA
- Vol. 332 (14) , 1208
State Biomarker Testing Insurance Coverage Laws—Reply
In Reply We appreciate the comments from Ms Lacasse and colleagues regarding our recently published Viewpoint examining the current landscape of state
- 11 June 2024
- Published by American Medical Association (AMA) in JAMA
- Vol. 331 (22) , 1885-1886
The State of State Biomarker Testing Insurance Coverage Laws
This Viewpoint discusses laws mandating insurance coverage of biomarker testing to broaden access to care for patients with cancer.
- 11 June 2024
- Published by American Medical Association (AMA) in JAMA
- Vol. 331 (22) , 1885-1886
The State of State Biomarker Testing Insurance Coverage Laws
This Viewpoint discusses laws mandating insurance coverage of biomarker testing to broaden access to care for patients with cancer.
- 18 August 2023
- Published by Elsevier in Healthcare
- Vol. 11 (3) , 100705
Reading the crystal ball: Primary care implications while awaiting outcomes for multi-cancer early detection tests
- 18 August 2023
- Published by Elsevier in Healthcare
- Vol. 11 (3) , 100705
Reading the crystal ball: Primary care implications while awaiting outcomes for multi-cancer early detection tests
- Open Access
- 1 November 2021
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 27 (11) , 1613-1617
The effectiveness and value of aducanumab for Alzheimer’s disease
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and E...
- 1 November 2021
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 27 (11) , 1613-1617
Open AccessThe effectiveness and value of aducanumab for Alzheimer’s disease
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and E...
- 7 July 2021
- Published by Wiley in Journal of Genetic Counseling
- Vol. 31 (1) , 130-139
Influence of payer coverage and out‐of‐pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings
The landscape of payment for genetic testing has been changing, with an increase in the number of laboratories offering testing, larger panel offerings, and lower prices. To determine the influence of payer coverage and out‐of‐pocket costs on the ordering of NGS panel tests for hereditary cancer in diverse settings, we conducted semi‐structured interviews with providers who conduct genetic counseling and order next‐generation sequencing (NGS) panels purposefully recruited from 11 safety‐net clinics and academic medical centers (AMCs) in California and North Carolina, states with diverse populations and divergent Medicaid expansion policies. Thematic analysis was done to identify themes related to the impact of reimbursement and out‐of‐pocket expenses on test ordering. Specific focus was put on differences between settings. Respondents from both safety‐net clinics and AMCs reported that they are increasingly ordering panels instead of single‐gene tests, and tests were ordered primarily from a few commercial laboratories. Surprisingly, safety‐net clinics reported few barriers to testing related to cost, largely due to laboratory assistance with prior authorization requests and patient payment assistance programs that result in little to no patient out‐of‐pocket expenses. AMCs reported greater challenges navigating insurance issues, particularly prior authorization. Both groups cited non‐coverage of genetic counseling as a major barrier to testing. Difficulty of access to cascade testing, particularly for family members that do not live in the United States, was also of concern. Long‐term sustainability of laboratory payment assistance programs was a major concern; safety‐net clinics were particularly concerned about access to testing without such programs. There were few differences between states. In conclusion, the use of laboratories with payment assistance programs reduces barriers to NGS panel testing among diverse populations. Such programs represent a major change to the financing and affordability of genetic testing. However, access to genetic counseling is a barrier and must be addressed to ensure equity in testing.
- 7 July 2021
- Published by Wiley in Journal of Genetic Counseling
- Vol. 31 (1) , 130-139
Influence of payer coverage and out‐of‐pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings
The landscape of payment for genetic testing has been changing, with an increase in the number of laboratories offering testing, larger panel offerings, and lower prices. To determine the influence of payer coverage and out‐of‐pocket costs on the ordering of NGS panel tests for hereditary cancer in diverse settings, we conducted semi‐structured interviews with providers who conduct genetic counseling and order next‐generation sequencing (NGS) panels purposefully recruited from 11 safety‐net clinics and academic medical centers (AMCs) in California and North Carolina, states with diverse populations and divergent Medicaid expansion policies. Thematic analysis was done to identify themes related to the impact of reimbursement and out‐of‐pocket expenses on test ordering. Specific focus was put on differences between settings. Respondents from both safety‐net clinics and AMCs reported that they are increasingly ordering panels instead of single‐gene tests, and tests were ordered primarily from a few commercial laboratories. Surprisingly, safety‐net clinics reported few barriers to testing related to cost, largely due to laboratory assistance with prior authorization requests and patient payment assistance programs that result in little to no patient out‐of‐pocket expenses. AMCs reported greater challenges navigating insurance issues, particularly prior authorization. Both groups cited non‐coverage of genetic counseling as a major barrier to testing. Difficulty of access to cascade testing, particularly for family members that do not live in the United States, was also of concern. Long‐term sustainability of laboratory payment assistance programs was a major concern; safety‐net clinics were particularly concerned about access to testing without such programs. There were few differences between states. In conclusion, the use of laboratories with payment assistance programs reduces barriers to NGS panel testing among diverse populations. Such programs represent a major change to the financing and affordability of genetic testing. However, access to genetic counseling is a barrier and must be addressed to ensure equity in testing.
- 1 November 2019
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 12 (11) , e006084
More Pills but Better Adherence?
- 1 November 2019
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 12 (11) , e006084
More Pills but Better Adherence?
- Open Access
- 1 October 2017
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 2 (10) , 1164-1166
Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans
Approximately 9 million US adults with atherosclerotic cardiovascular disease or familial hypercholesterolemia do not achieve optimal levels of low-density lipoprotein cholesterol despite maximally tolerated statin therapy.1 Adding a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) may significantly lower low-density lipoprotein cholesterol levels and reduce the risk of myocardial infarction and stroke.2 However, PCSK9is are expensive, with annual costs exceeding $14 500.1 Understanding patients’ share of drug costs is important because high out-of-pocket costs can adversely affect affordability and adherence to lifelong treatment.3 Because 1 in 4 Medicare beneficiaries has ischemic heart disease and nearly 1 in 2 has hyperlipidemia,4 we examined PCSK9i cost-sharing requirements for Medicare Part D plans nationwide, which insure 41 million beneficiaries.5
- 1 October 2017
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 2 (10) , 1164-1166
Open AccessNationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans
Approximately 9 million US adults with atherosclerotic cardiovascular disease or familial hypercholesterolemia do not achieve optimal levels of low-density lipoprotein cholesterol despite maximally tolerated statin therapy.1 Adding a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) may significantly lower low-density lipoprotein cholesterol levels and reduce the risk of myocardial infarction and stroke.2 However, PCSK9is are expensive, with annual costs exceeding $14 500.1 Understanding patients’ share of drug costs is important because high out-of-pocket costs can adversely affect affordability and adherence to lifelong treatment.3 Because 1 in 4 Medicare beneficiaries has ischemic heart disease and nearly 1 in 2 has hyperlipidemia,4 we examined PCSK9i cost-sharing requirements for Medicare Part D plans nationwide, which insure 41 million beneficiaries.5